Kornimate/medical-research-clean huggingface dataset:
risk factors for acute kidney injury in patients undergoing arthroplasty

Conditions: Postoperative Acute Kidney Injury; Arthroplasty

Summary: the authors aimed to determine the risk factors associated with postoperative acute kidney injury in patients undergoing total joint arthroplasty.

aim: the primary aim of the current study is to determine the risk factors associated with postoperative acute kidney injury in patients undergoing total joint arthroplasty. considering that this patient group is mostly composed of advanced age and comorbid patients, the secondary aim of the study is to identify risky patients with predictable risk factors and to chart a way to make preoperative optimizations of the patients before developing postoperative complications. materials and methods: patients who underwent joint arthroplasty between 2015 and 2020 in ankara university faculty of medicine, department of orthopedics and traumatology were included. within the scope of the study, patients' gender, age, weight, height, body mass index values, smoking, american society of anesthesiologist (asa) score, charlson-comorbidity index score (cci), type of operation, duration of surgery, presence of intraoperative hypotension, anesthesia method , diabetes, hypertension, coronary artery disease, presence of congestive heart failure, presence of preoperative anemia, preoperative uric acid and albumin level, use of nephrotoxic agents in the perioperative period, basal creatinine and glomerular filtration rate (gfr) values, platelet suspension in the perioperative period, erythrocyte suspension, amounts of fresh frozen plasma transfusions, postoperative creatinine at 24 hours - 48 hours - discharge, gfr values and kidney disesae improving global outcomes (kdigo) scores, length of hospital stay and length of stay in the intensive care unit were evaluated.

Eligibility criteria:
inclusion criteria: * patients aged above 18 years old undergoing arthroplasty surgery exclusion criteria: * known acute renal failure or chronic renal failure * patients aged below 18 years old * patients refusing to participate to the study

Keywords: arthroplasty acute kidney injury
utilization of 31p-nuclear magnetic resonance spectroscopy to monitor brain energy deficit in huntington disease

Conditions: Huntington Disease

Summary: the purpose of this project is to study brain energy profile evolution at different stages of the huntington disease.


Eligibility criteria:
inclusion criteria: * uhdrs \< 50 * age \> 18 years * ability to undergo mr scanning * covered by french social security exclusion criteria: * evidence of psychiatric disorder * attendant neurological disorder * contraindications to mri (claustrophobia, metallic or material implants) * severe head injury * unable to understand the protocol * pregnancy * failure to give informed consent * subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent) * unwillingness to be informed in case of abnormal mri
blood flow restriction after meniscus repair

Conditions: Meniscus Disorder; Meniscus, Torn Tibial; Meniscus Lesion; Meniscus Tear, Tibial; Atrophy, Muscular

Summary: the purpose of this study is to evaluate post-operative outcomes after meniscus surgery in participants undergoing blood flow restriction training as a rehabilitative adjunct compared to those with standard rehabilitation.

the investigators will conduct a double-blinded, single-institution, randomized controlled trial to compare patients undergoing arthroscopic meniscus repair with post-operative rehabilitation protocol as (1) a standard-of-care rehabilitative protocol with a non-occlusive blood pressure cuff (inflated to 20-30 mm hg) applied to the operative extremity versus (2) blood flow restriction training with cuff occlusion applied to the operative extremity. patients will be enrolled prospectively and pre-operatively at their initial clinic visit after meniscus injury. rehabilitative exercises would be advanced per the physical therapists' discretion with similar exercises for patients in both groups for direct comparison. these exercises are part of an already-established post-operative protocol that is in place, with the only difference being the addition of the blood flow restriction protocol in the intervention group. all patients would undergo their supervised post-operative rehabilitation at our institution.

Eligibility criteria:
inclusion criteria: * participants who undergo surgery for arthroscopic meniscus repair exclusion criteria: * participants undergoing surgery for concomitant ligamentous surgeries * patients with diabetes mellitus, vascular disease, or infections of the involved extremity

Keywords: blood flow restriction rehabilitation meniscus repair
analysis of muscular properties in patients with mfs and eds

Conditions: Rare Diseases; Marfan Syndrome; Ehlers-Danlos Syndrome

Summary: the goal of this observational study is to learn and assess muscle morphological and electromechanical properties in patients affected with marfan syndrome (mfs) and ehlers danlos syndrome (eds). the main questions it aims to answer are: * to assess the ability to develop muscle strength; * muscle and tendon morphology involved in muscle contractions/relaxation; * neuromuscular functionality. participants will be take part in the study by performing a test for the assessment of the neuromuscular activity (voluntary muscle contractions) and undergoing a muscle ultrasound for the study of muscles and tendons. researchers will compare the two groups with a control group to see potential differences in the morphological and neuromuscular structures of syndromic patients.

mfs, with an autosomal dominant inheritance, can lead to the presence of pathological systemic/syndromic phenotypes. despite the cardiovascular involvement is responsible for the high mortality and morbidity, the skeletal system and the muscular system also present alterations at the metabolic level. like mfs, ehlers-danlos syndrome (eds) is a rare autosomal dominantly inherited connective tissue disorder. eds is caused by mutations that cause impaired collagen production, therefore of pathological phenotypes affecting connective tissues such as the integumentary system, the system skeletal system, the cardiovascular system and other organs and tissues. joint dislocations, musculoskeletal pain, atrophic scarring, and severe scoliosis may occur in patients with eds. to date, there are no studies in literature assessing neuromuscular properties in patients with mfs and eds. however, the analysis of the musculo-tendon morphological and mechanical properties makes it possible to evaluate the muscle capacity especially in pathological conditions, where the morphology and tendon mechanics are altered, thus providing pivotal information on changes in the contractile capacity of the muscle.

Eligibility criteria:
inclusion criteria: * diagnosis of marfan syndrome or ehlers danlos syndrome currently in follow-up at cardiovascular genetic centre irccs policlinico san donato; * signed informed consent; exclusion criteria: * previous muscle-tendon injuries in the lower and/or upper limbs; * presence of cardiac pacemaker; * epilepsia; * presence neurological disorders or circulatory diseases in the lower limbs; * pregnancy.

Keywords: rare diseases; fatigue; muscle
impact of concussion history on sleep and physical performance in contact sports athletes

Conditions: Concussion, Mild; Sleep; Physical Performance

Summary: this study investigates the correlation between a history of concussions and its effects on both sleep patterns and physical performance among athletes engaged in contact sports. by examining the relationship between concussion history, sleep quality, and athletic performance, this research aims to provide insights into the potential long-term implications of concussions on the well-being and performance of athletes in contact sports

this study delves into the intricate relationship between the history of concussions, sleep quality, and physical performance among athletes participating in contact sports. concussions, often occurring due to the high-impact nature of these sports, have raised concerns regarding their potential long-term effects on athletes' health and performance. this research aims to elucidate whether a history of concussions influences athletes' sleep patterns and subsequently affects their physical performance. the study employs a comprehensive approach, utilizing both subjective and objective measures to assess sleep quality, such as self-reported sleep disturbances and objective sleep monitoring techniques. furthermore, various metrics are employed to evaluate physical performance, including agility, strength, speed, and endurance tests tailored to the specific demands of contact sports. by analyzing the data collected from athletes with and without a history of concussions, the study aims to identify potential correlations between concussion history, sleep disturbances, and diminished physical performance. additionally, the research seeks to uncover any potential mediating factors, such as psychological distress or neurocognitive deficits, which may contribute to these associations. the findings of this study hold significant implications for athlete well-being and sports medicine practices. understanding the impact of concussions on sleep quality and physical performance can inform tailored interventions and rehabilitation strategies to mitigate the adverse effects of concussions on athletes' health and optimize their performance outcomes in contact sports. moreover, these insights may contribute to the development of preventive measures and policies aimed at reducing the incidence and severity of concussions in sports settings.

Eligibility criteria:
inclusion criteria: participants falling in this category would be recruited into the study. * active male combat sports player. * age between 18-25 years. * athletes who had a hit on jaw, neck, head and had symptom of concussion discussed under heading of introduction. * athlete who had history of concussion between 3-30 days. * mild concussion according to cantu no loc pta exclusion criteria: participants fall in this category would be excluded of the study. * concussion other than sports. * history of metabolic diseases. * history of recent fractures

Keywords: contact sports
a study to evaluate the efficacy and safety of hr19042 capsules in the treatment of primary iga nephropathy.

Conditions: IgA Nephropathy

Summary: this study will evaluate the efficacy and safety of hr19042 capsules compared to matching placebo for the treatment of primary iga nephropathy, and explore the optimal dose for the treatment.


Eligibility criteria:
inclusion criteria: 1. female or male patients ≥18 years old； 2. biopsy-confirmed primary iga nephropathy； 3. urine protein≥0.75 g/24hr or urine protein creatinine ratio (upcr)≥0.5 g/g； 4. estimated gfr (using the ckd-epi2009 formula) ≥30ml/min/1.73 m2； 5. willing and able to take adequate contraception during the trial; 6. willing and able to give informed consent and follow the protocols during the trial. exclusion criteria: 1. systemic diseases which could lead to secondary iga nephropathy； 2. patients with severe chronic infection or active infection under systemic antibiotic therapy in previous 14 days； 3. patients with severe cardiovascular diseases； 4. patients diagnosed with malignancy within the past 5 years； 5. patients with liver cirrhosis； 6. patients received organ transplantation； 7. patients with uncontrolled type 1 or 2 diabetes； 8. positive results in hiv-ab/tp-ab/ hbsag/hcv-ab tests； 9. patients treated with any systemic immunosuppressive drugs (excluding corticosteroids) within the past 12 months before screening； 10. patients treated with any systemic corticosteroids within the past 3 months before screening.
impact in off-spring of mothers after perinatal daily intake of a probiotic

Conditions: Asthma; Dermatitis, Atopic; Rhinitis, Allergic, Perennial

Summary: a probiotic (lactobacillus rhamnosus gg) supplement to pregnant women the last four weeks of pregnancy and three months after birth is expected to give a 40% reduction in risk of atopic sensitisation and allergic disease at two years of age, compared to placebo.

to investigate how probiotics given to pregnant women during the last 4 weeks of pregnancy and the first 4 months after birth influence the establishment and composition of the gut microflora in children from birth until two years of age. at the same time to investigate the relationship between gut flora composition and the development of the immune system. to investigate the relationship between supplement of probiotics to pregnant and breast-feeding women, the microbial composition of the gut flora in their children, the development of the childrens' immune system, and the prevalence of atopic sensitisation and atopic disease at two years of age.

Eligibility criteria:
inclusion criteria: * all pregnant women understanding norwegian language and who has signed an informed consent form, can be included. * inclusion must take place before week 36 in the pregnancy. * the woman must plan to breast-feed the first 4 months after birth. * she must live in trondheim. exclusion criteria: * not being able to fill in the questionnaire in norwegian language * lactose intolerance * consumption of probiotics earlier in the pregnancy. * intention to move from trondheim in the next 25 months. * pregnant women in risk of eclampsia, or other serious disease that can influence beast-feeding or care for the child.

Keywords: prevention probiotics allergy hypersensitivity
study of maraviroc (mvc) and epzicom (abc/3tc) once-daily in art-naive & first switch patients

Conditions: Drug-induced Hypotension

Summary: hypotension does not occur with maraviroc at a dose of 600 mg/day

a qualitative description of orthostatic hypotension in patients receiving once daily maraviroc at 600 mg with epzicom measured by a validated questionnaire

Eligibility criteria:
inclusion criteria: * epzicom maraviroc once daily dosing exclusion criteria: * maraviroc with any other back bone
rosuvastatin on diabetic patients treated with glimepiride/metformin

Conditions: Diabetes Mellitus, Type 2

Summary: study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease. this effect will be investigated especially on sortilin ,fetuin-a

a randomized controlled trial on 70 patients with dm type 2 will be recruited from damanhour national medical institute. * subjects will be divided into two group (one arm is dm-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is dm-type 2 patient who will receive glimepiride-metformin combination (30 patients). * determination of serum levels of fetuin a and sortilin * blood samples will be collected after 3-month after active treatment. * outcomes measurement : sortilin ,fetuina, atherogenic index (ai) and coronary risk index (cri) . methodology * sortilin, fetuina will be determined by elisa. * lipid profile. * fbg and hb a1c will be measured. * atherogenic index (ai = ldl-c/hdl-c) and cri (cri = tc/hdl-c) will be calculated for all subjects.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus on oral therapy. * age 21-65 years * life expectancy \>1 year. exclusion criteria: * documented cvd * planned surgical intervention. * hypersensitivity to either of the study drug components. * type i diabetes. * current insulin treatment. * hepatic impairment known hepatic failure. * inability to comply with study protocol. * active malignancy. * chronic inflammation (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection). * pregnancy, lactation or child-bearing potential. * chronic renal disease

Keywords: t2dm.
the impact of oncoplastic breast surgery on the oncological safety and patient satisfaction

Conditions: Non Metastatic Breast Cancer

Summary: the aim of this study is to asses the oncological safety of oncoplastic breast surgery, its impact on patient satisfaction and is it worthy for general breast surgeon to learn different oncoplastic techniques.

this non randomized prospective trial was conducted on 70 female patients presented to our tertiary referral breast unit -ain shams university hospitals with non metastatic breast cancer during the period from september 2012 to september 2013. all of them signed an informed consent to share in this study that was approved in the ethical committee held on april 2012 - ain shams university. our patients were divided into 2 equal groups: group a (35patients) who underwent standard quadrantectomy, group b (35 patients) who underwent oncoplastic surgery. in group a all quadrantectomies were done by general breast surgeons while in group b the oncoplastic procedures were done by well trained oncoplastic breast surgeons not assisted by plastic surgeons. the following data were reported in all cases including: age, family history, tumor size, volume and weight of the specimen, location of tumor, margin length, (primary tumor, regional nodes, metastasis) staging, molecular subtype and patient satisfaction.

Eligibility criteria:
inclusion criteria: * stage 1, 2 breast cancer * non metastatic breast caner * singing informed consent exclusion criteria: * metastatic breast cancer * stage 3, 4 breast cancer * inflammatory breast cancer * multicentric/multifocal disease * ductal carcinoma in situ * patients older than 60 years * history of breast surgery in oncoplastic group * co-morbidity in oncoplastic group * patients more than 60 years old

Keywords: oncoplastic breast surgery oncological safety patient satisfaction
efficacy and safety of rimonabant with or without hypocaloric diet in obese patients

Conditions: Obesity

Summary: the primary objective of this study is to assess the effect of rimonabant on the energy intake (kcal/day/meal) from ad-libitum high-fat dinner (primary endpoint), pre- and post-ingestive responses, and the hedonic evaluation of food, and its effect on food choice, cravings and feelings of control. the secondary objectives are to determine the effect of rimonabant on body weight with or without hypocaloric diet and its clinical and laboratory safety.


Eligibility criteria:
inclusion criteria: * obese subjects with body mass index ≥ 30 and \< 45 kg/m² the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: hypocaloric diet energy intake
retrospective analysis on relapsed/refractory aggressive non hodgkin lymphoma treated with z-beam plus asct

Conditions: Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma

Summary: evaluate if y90 ibritumomab tiuxetan radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non hodgkin lymphoma


Eligibility criteria:
inclusion criteria: * high risk relapsed/refractory aggressive non-hodgkin lymphoma defined as: * progressive disease * early relapse (within 12 months from response) * recurrent relapse * treated with salvage chemotherapy followed by y90 ibritumomab tiuxetan plus high-dose chemotherapy and autologous stem cell transplant * age \> 18 years * previous treatment with rituximab * written informed consent exclusion criteria: * patient with no complete data available for collection

Keywords: aggressive b-cell non-hodgkin lymphoma relapsed refractory zevalin y90 ibritumomab tiuxetan autologous stem cell transplant beam recurrent
intravenous val-1221 lafora expanded access protocol

Conditions: Lafora Disease

Summary: only qualified physicians treating a lafora disease patient may request val-1221 expanded access treatment under the parasail lafora expanded access protocol (leap). according to fda guidance, this protocol can enroll up to 10 patients. however, individual patient inclusion will ultimately be dependent on protocol eligibility, site geography, treatment requirements, and available supply of the investigational therapy. inquiring physicians can submit a request by contacting the central contact personnel listed below in contacts/locations.


Eligibility criteria:
inclusion criteria: * documented genetic diagnosis of lafora disease (ld) based on likely pathogenic or pathogenic variants in both alleles of either the epm2a or the epm2b gene * mid-stage in evolution of ld between 12 and 28 years of age * able and willing to comply with the protocol, including travel to protocol center, procedures, measurements and visits, including: * adequately supportive psychosocial circumstances, in the opinion of the investigator * caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age exclusion criteria: * have any other conditions, which, in the opinion of the investigator or sponsor would make the participant unsafe for inclusion or could interfere with the participant participating in or completing the protocol

Keywords: glycogen storage diseases polyglucosan disorders progressive myoclonic epilepsy
a natural history study to assess the clinical outcomes of patients with complement factor i deficiency-mediated disease

Conditions: Recurrent Bacterial Infection, Autoimmune Disorder

Summary: this study will follow participants with a disease which is associated with an absence or deficiency in complement factor i (cfi) as confirmed in the cfi-001 screening study.

this study will follow participants with a disease which is associated with an absence or deficiency in complement factor i (cfi) as confirmed in the cfi-001 screening study. the population will include male and female participants ≥6 months of age (pediatric participants enrolled as permitted by local institutional review board/independent ethics committee). this includes patients with recurrent bacterial infections (eg, meningitis, sepsis, pneumonia, endocarditis, otitis) and patients with autoimmune and immune complex-mediated diseases (eg, glomerulonephritis, systemic lupus erythematosus, leukocytoclastic vasculitis, bickerstaff encephalitis, meningoencephalitis).

Eligibility criteria:
inclusion criteria: 1. male or female, age 6 months or older 2. affirmation of participant's informed consent or legally authorized representative (lar)'s willingness to provide informed consent with signature confirmation before any study-related activities. (study-related activities are any procedures that would not have been performed during normal clinical management of the participant.) the participant (if a minor) must also be willing to give written informed assent (if able) if the minor is within the age groups 7 to 11 years old and 12 to 17 years old. 3. confirmed cfi deficiency during the screening study, cfi-001, with a disease that is associated with an absence or deficiency in cfi 4. stated willingness of the participant to comply with all study procedures (including multiple blood draws) and availability for the duration of the study 5. stated willingness of the participant (or lar) to allow access to his/her medical records with the purpose of assessing disease status and progression during his/her participation in the study exclusion criteria: 1. participation in an interventional clinical study within the previous 30 days prior to screening or within ≤5 half-lives of the investigational drug, whichever is longer 2. having a major concurrent non-cfi-related disease that prevents the assessment of the natural course of the cfi deficiency disease 3. having a medical, psychosocial, or familial issues that might prevent full participation and cooperation with the procedures and requirements of the clinical study as determined by the potential participant/guardian and physician investigator